Phase 2 N=473 Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Lymphoma
Primary: Number of Participants With 1 Year Progression Free Survival — 112; 102; 1; 2 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=119 Comparative Effectiveness of Early Physical Therapy Versus Usual Care for Low Back Pain
Low Back Pain
Primary: Modified Oswestry Disability Index — 23.46; 24.26 score on a scale
N/A N=416 Trial of KEEP-P, a Preventive Intervention for Foster Preschoolers (KEEP-P)
Child Behavior
Primary: Parenting Stress Via Self-report Measure Parenting Stress Index IV (PSI-IV) Short Form — 80.87; 86.18; 74.62; 80.8 score on a scale
Phase 2 N=3 A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Von Hippel-Lindau Syndrome
Primary: Tabulation of Adverse Events — 13 adverse events
Phase 2 N=102 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma
Primary: Response Rate — 9; 2 Participants
N/A N=288 Enhancing Mental Health Care by Scientifically Matching Patients to Providers' Strengths
Mental Illness
Primary: Average Z-Scores for the Treatment Outcome Package-Clinical Scales (TOP-CS; Kraus, Seligman, & Jordan, 2005) — 0.57; 0.56 units on a scale — p=.02
Phase 2 N=81 Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis
Atopic Dermatitis
Primary: Change From Baseline in Total Sign Score (TSS) in Target Lesions at Day 15: Crisaborole Ointment 2% Versus Vehicle — 7.7; 7.5; 7.1; 7.4 units on a scale — p=0.0071
N/A N=35 Balance Recovery Training for Fall Prevention in Retirement Communities
Accidental Falls, Aged, Exercise Movement Techniques
Primary: Maximum Torso Angle at 0.8 Mph — 18.8; 23.9; 20.5; 11.7 degrees
Phase 1 N=16 Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent
HIV Infections
Primary: Area Under the Concentration (AUC) Time Curve From Time Zero Extrapolated to Infinite Time (AUC [0-infinity]) of DTG — 90.9402 Hours*micrograms per milliliter
Phase 2 N=61 Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension
Primary: Change From Baseline in Pulmonary Vascular Resistance (PVR) — 514.6; 512.0 dyn*sec/cm^5 — p=0.0220
N/A N=88 Non-invasive CTS Device Clinical Trial
Carpal Tunnel Syndrome
Primary: BCTQ SSS at 8 Weeks vs Baseline — 2.16; 2.32; -0.62; -0.64 score on a scale
N/A N=36 Emergence From Anesthesia in Anterior Temporal Lobectomy and Amygdalohippocampectomy Patients
Emergence From Anesthesia
Primary: Volumes of the Hippocampus, Thalamus and Amygdala — 3578; 3903; 3479; 3525 mm3
N/A N=151 Clinical Comparison of DDT2 Contact Lens and a Daily Disposable Contact Lens - Study 2
Refractive Error · Myopia
Primary: Least Squares Mean Distance Visual Acuity With Study Lenses — -0.08; -0.08 logMAR
Phase 3 N=900 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine
Healthy Volunteers
Primary: Percentage of Participants HAV/Dengue Virus (DENV)-Naive at Baseline Who Are Seroprotected Against HAV at Day 30 — 97.1; 9.1; 98.7 percentage of participants
Phase 3 N=111 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Leukemia, Acute Lymphoblastic
Primary: Kaplan Meier Estimate: Event-Free Survival (EFS; Primary Analysis) — 7.4; NA months — p=< 0.001